Journal
ONCOTARGETS AND THERAPY
Volume 14, Issue -, Pages 2823-2828Publisher
DOVE MEDICAL PRESS LTD
DOI: 10.2147/OTT.S294635
Keywords
afatinib; leptomeningeal metastasis; EGFR; ALK; co-alterations; lung adenocarcinoma
Categories
Ask authors/readers for more resources
LM is a severe complication of LAC, and EGFR/ALK co-alterations are rare. Treatment with afatinib led to improved symptoms and reduced lesions in a patient with EGFR and EML4-ALK mutations.
Leptomeningeal metastasis (LM) is a disastrous complication of advanced lung adenocarcinoma (LAC) associated with poor prognosis and rapid deterioration of performance status. The prevalence of epidermal growth factor receptor (EGFR)/anaplastic lymphoma kinase (ALK) co-alterations in patients with LAC was low. Herein, we report a patient with alterations in both EGFR (p. G719A+L747V) and echinoderm microtubule-associated protein-like ALK (EML4-ALK) fusion and LM who was treated with afatinib. The patient's clinical symptoms improved, and imaging examination revealed reduced intracranial and extracranial lesions. The progression-free survival (PFS) using afatinib for LM was 25 months, and no severe adverse events occurred.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available